Julian Schink, MD
Cancer Treatment Centers of America (CTCA) has named Julian Schink, MD, as Chief of Gynecologic Oncology. He will also serve as Medical Director of Gynecologic Oncology and Medical Oncology at CTCA at the Midwestern Regional Medical Center in Zion, Illinois.
A nationally renowned, Board-certified gynecologic oncologist, Dr. Schink brings more than 30 years of oncology experience to the organization, specializing in surgery, chemotherapy, hormone therapy, and targeted therapies for patients with gynecologic cancers. Dr. Schink will oversee the national Gynecologic Oncology Program at CTCA, serving patients in the treatment of cervical, ovarian, uterine, vaginal, and vulvar cancers, as well as gestational trophoblastic diseases. Under the guidance of Dr. Schink, the CTCA Gynecologic Oncology Program will include robotic surgery, a national gynecologic tumor board, and hyperthermic intraperitoneal chemotherapy.
“As a gynecologic oncologist, my single, most important goal is to fight cancer, and I am honored to join a premier leader in treating people living with cancer and one that shares my commitment to delivering high-quality, personalized care to patients,” said Dr. Schink. “Advances in gynecologic oncology, including robotic surgery, have helped cancer patients become survivors and are evolving every day. Through the national Gynecologic Oncology Program at CTCA, my goal is to ensure we help advance these innovations to meet the needs of patients when they need us most.”
Dr. Schink joins CTCA from Spectrum Health, where he served as Vice President of Improvement and Integration. He has held numerous academic positions, including Vice Chair of Obstetrics and Gynecology and Professor at the University of Wisconsin Medical School; John I. Brewer Professor of Gynecology and Cancer Research at Northwestern University Feinberg School of Medicine; and Professor of Obstetrics and Gynecology at Michigan State University. He has also served as principal investigator and co-investigator for many large clinical trials responsible for improving and expanding cancer treatment options. ■